Idorsia’s treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product’ category

Core Viewpoint - Idorsia Ltd has received the inaugural Prix Galien Bridges Award for its innovative treatment for insomnia disorder, highlighting the company's commitment to advancing patient care through scientific innovation [1][8]. Company Overview - Idorsia is focused on developing transformative medicines and aims to evolve into a leading biopharmaceutical company with a strong scientific foundation [13][14]. - The company is headquartered near Basel, Switzerland, and is listed on the SIX Swiss Exchange under the ticker symbol IDIA [14]. Product Details - The awarded treatment is a dual orexin receptor antagonist, recognized as the first and only drug of its kind approved in Europe for insomnia disorder [8][11]. - The development process involved synthesizing and characterizing over 25,000 compounds over a span of more than 10 years to achieve a drug that effectively improves both nighttime sleep and daytime functioning [3][11]. Recognition and Awards - The Prix Galien Awards, established in 1970, are considered the equivalent of the Nobel Prize for the life sciences industry, recognizing outstanding innovation and scientific advancement [3][5]. - The award received by Idorsia is particularly significant as it is the first of its kind in the Nordics, underscoring the company's innovative contributions to healthcare [2]. Insomnia Disorder Context - Insomnia disorder affects approximately 9.2% of the working-age population in Switzerland, characterized by difficulty in initiating or maintaining sleep, leading to significant daytime impairment [7][6]. - The orexin system plays a crucial role in regulating wakefulness, and its antagonism is key to restoring natural sleep architecture in patients with insomnia [10][11].